Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) Sees Large Drop in Short Interest

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) was the recipient of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 327,700 shares, a decline of 39.8% from the January 15th total of 544,600 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is presently ∞ days.

Hansa Biopharma AB (publ) Price Performance

Shares of OTCMKTS HNSBF opened at $3.00 on Friday. The firm has a fifty day moving average of $2.95 and a 200-day moving average of $3.08. Hansa Biopharma AB has a 52-week low of $2.83 and a 52-week high of $3.65.

Hansa Biopharma AB (publ) Company Profile

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test.